Order Article Reprints

Barsegian V, Möckel D, Buehler S, Müller SP, Kreissl MC, Ostheim P, Horn PA, Lindemann M. Lymphocyte Function at Baseline Could Be a New Predictor of Tumor Burden following Six Cycles of Radium-223 Therapy in Patients with Metastasized, Castration-Resistant Prostate Cancer. Cancers. 2024; 16(5):886. https://doi.org/10.3390/cancers16050886

Barsegian, Vahé, Daniel Möckel, Sebastian Buehler, Stefan P. Müller, Michael C. Kreissl, Patrick Ostheim, Peter A. Horn, and Monika Lindemann. 2024. "Lymphocyte Function at Baseline Could Be a New Predictor of Tumor Burden following Six Cycles of Radium-223 Therapy in Patients with Metastasized, Castration-Resistant Prostate Cancer" Cancers 16, no. 5: 886. https://doi.org/10.3390/cancers16050886

Barsegian, V., Möckel, D., Buehler, S., Müller, S. P., Kreissl, M. C., Ostheim, P., Horn, P. A., & Lindemann, M. (2024). Lymphocyte Function at Baseline Could Be a New Predictor of Tumor Burden following Six Cycles of Radium-223 Therapy in Patients with Metastasized, Castration-Resistant Prostate Cancer. Cancers, 16(5), 886. https://doi.org/10.3390/cancers16050886